News and trends on diagnostics testing, insurance coverage, and reimbursement.
The agency is excluding certain advanced diagnostic lab tests and molecular pathology tests from a billing regulation that created administrative headaches for many labs.
Anthem said the automated system is an efficient way to ensure coverage for medically necessary genetic tests, but that's not what genetic counselors have described.
Smaller labs, hospital outreach labs, and labs servicing high numbers of elderly are thought to face the highest risks.
Piper Jaffray analyst William Quirk said the pricing, which was much higher than expected, will help push CareDx toward profitability.
The biggest losers following the release of the preliminary PAMA rates may be Quest and LabCorp, analysts said today.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.
Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.